SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: I. Luttichuys who wrote (1073)6/27/1997 1:32:00 AM
From: Roger Cranwill   of 1762
 
ECG-We can only hope your prediction pans out! One thing I see with CE9.1 is that the CD4 depression was a known, and that it was decided to proceed to phase III anyway. The only point being at variance is the percentage of patients with the lower CD4 count. If the depression was not considered a troubling factor, only the methods of determining the variance would be evaluated. When you look at other drugs, particularly chemotherapy, some pretty serious side-effects are figured into the balance of risk of side effects vs efficacy of the drug. I think 9.1 still has a chance-as you know, Bennett, even the NSAIDS have quite a long list of warnings as far as liver and renal damage, GI bleeding, etc. There is no such thing as a perfect drug. Roger
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News